Sarepta Therapeutics [SRPT] - Last Close: $123.50
The FDA has approved a labeled indication for Sarepta’s Elevidys that would expand its use to include individuals with Duchenne muscular dystrophy.
U.S. drug regulators made the call after confirming the drug’s functional benefits.
Elevidys is currently undergoing a Phase 3 trial in non-ambulatory and older ambulatory individuals with Duchenne.
SRPT is up 34.4% on roughly half-a-million shares traded.
My Take: SRPT could be onto something big here. It’s currently on pace to set a new 52-week high, but its nearest verifiable support is all the way down at $140 per share.
Spectaire Holdings [SPEC] - Last Close: $0.34
After Thursday’s close, Spectaire Holdings filed a Form 8-K announcing several favorable deals.
The company made a deal with a law firm to reduce its balance owed from $6.2 million to just $2.74 million
Spectaire also entered into a settlement agreement Jefferies regarding fees owed, and it made a deal to acquire $600K assets from Corsario Ltd. in exchange for 1.5 million shares of SPEC.
SPEC is today’s top premarket mover with a 104% gain on over 17 million shares traded.
My Take: SPEC has had a busy couple of weeks negotiating all these deals. These positive catalysts could help the company pivot out of its downtrend. .
36Kr Holdings [KRKR] - Last Close: $0.3440
36Kr just dropped a buzzword-filled press release announcing a collaboration with SenseTime that would give them access to sophisticated AI tools.
The company plans to “embed artificial general intelligence technology in diverse media scenarios,” whatever that means.
36Kr also claimed that the deal will allow it to reach a much broader base of enterprise customers.
KRKR is a top mover with a 47.9% gain on over 23 million shares traded.
My Take: KRKR is riding yet another AI buzzword rally, and the move looks way overdone to me.
Ascent Solar Tech [ASTI] - Last Close: $0.1079
Early this morning, Ascent Solar announced a debt pay-off for outstanding balances related to a 2022 Securities Purchase Agreement.
The company said it has paid all remaining obligations to the institutional investor, including notes payable and related liabilities.
ASTI is up 23.1% on roughly 58 million shares traded this morning.
My Take: ASTI has has a tough year, and, while I don’t think this pay-off is enough to fuel a turnaround, it certainly doesn’t hurt.
| 